Maze Therapeutics Exchanges 2,776,007 Common Shares for Pre-Funded Warrants

• Maze Therapeutics exchanged 2,776,007 common shares held by Frazier Life Sciences funds for pre-funded warrants on October 15, 2026.
• The warrants cover 2,776,007 common shares at an exercise price of $0.001 per share.
• Exercise is permitted immediately but restricted if holders’ beneficial ownership would exceed 9.99%, subject to certain exceptions.
• Outstanding common shares totaled 53,931,889 as of October 16, 2026, following the exchange.
• The warrants will be issued without registration under the Securities Act, relying on the Section 3(a)(9) exemption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-424067), on October 16, 2026, and is solely responsible for the information contained therein.